JP2017520613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520613A5 JP2017520613A5 JP2017503504A JP2017503504A JP2017520613A5 JP 2017520613 A5 JP2017520613 A5 JP 2017520613A5 JP 2017503504 A JP2017503504 A JP 2017503504A JP 2017503504 A JP2017503504 A JP 2017503504A JP 2017520613 A5 JP2017520613 A5 JP 2017520613A5
- Authority
- JP
- Japan
- Prior art keywords
- oxy
- compound
- pharmaceutically acceptable
- acceptable salt
- tetrahydropyrrolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- VYMXZQQIOZTTMU-CYBMUJFWSA-N O=C(N(C[C@@H]1N2CCC1)C2=C1)N=C1OCc(cc1F)cc(F)c1Oc1ccnc(C(F)(F)F)c1 Chemical compound O=C(N(C[C@@H]1N2CCC1)C2=C1)N=C1OCc(cc1F)cc(F)c1Oc1ccnc(C(F)(F)F)c1 VYMXZQQIOZTTMU-CYBMUJFWSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000695 | 2014-07-22 | ||
| CNPCT/CN2014/000695 | 2014-07-22 | ||
| PCT/CN2015/084607 WO2016011931A1 (en) | 2014-07-22 | 2015-07-21 | Compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017520613A JP2017520613A (ja) | 2017-07-27 |
| JP2017520613A5 true JP2017520613A5 (enExample) | 2018-08-23 |
| JP6625603B2 JP6625603B2 (ja) | 2019-12-25 |
Family
ID=55162512
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017503504A Active JP6625603B2 (ja) | 2014-07-22 | 2015-07-21 | 化合物 |
| JP2017503553A Active JP6625604B2 (ja) | 2014-07-22 | 2015-07-21 | 化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017503553A Active JP6625604B2 (ja) | 2014-07-22 | 2015-07-21 | 化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US10125141B2 (enExample) |
| EP (2) | EP3172208B1 (enExample) |
| JP (2) | JP6625603B2 (enExample) |
| KR (2) | KR20170029516A (enExample) |
| CN (2) | CN106536521B (enExample) |
| AR (1) | AR101261A1 (enExample) |
| AU (2) | AU2015292048B2 (enExample) |
| BR (1) | BR112016030939B1 (enExample) |
| CA (2) | CA2955910C (enExample) |
| ES (2) | ES2747636T3 (enExample) |
| RU (2) | RU2690190C2 (enExample) |
| TW (1) | TW201617348A (enExample) |
| UY (1) | UY36224A (enExample) |
| WO (2) | WO2016011931A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR101261A1 (es) | 2014-07-22 | 2016-12-07 | Glaxosmithkline Ip Dev Ltd | Compuesto de tetrahidropirrolo[1,2:3,4]imidazo[1,2-c]pirimidin-1(6h)-ona y composición farmacéutica que lo comprende |
| US11273176B2 (en) | 2016-03-02 | 2022-03-15 | The Brigham And Women's Hospital, Inc. | Use of PLA2G5-deficient suppressive macrophages in suppression of inflammation |
| WO2019063634A1 (en) * | 2017-09-26 | 2019-04-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | DARAPLADIB RADIOMARQUÉ, ITS ANALOGUES AND THEIR USE AS IMAGING COMPOUNDS |
| CN109988126B (zh) * | 2017-12-29 | 2023-05-16 | 南京富润凯德生物医药有限公司 | 一种3-氨基-氧杂环丁烷衍生物及其制备方法和应用 |
| CN109134523A (zh) * | 2018-09-30 | 2019-01-04 | 中昊(大连)化工研究设计院有限公司 | 一种3，6-二氢-2h-吡喃-4-硼酸频哪醇酯的合成新工艺 |
| JP2022116370A (ja) * | 2019-06-13 | 2022-08-10 | アグロカネショウ株式会社 | 新規な１－ベンジルアミン誘導体及びこれを有効成分とする農園芸用薬剤 |
| CN112574221B (zh) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | 四环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| EP4056571A4 (en) * | 2019-11-09 | 2024-01-24 | Shanghai Simr Biotechnology Co., Ltd. | Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof |
| WO2021228159A1 (zh) * | 2020-05-13 | 2021-11-18 | 上海纽思克生物科技有限公司 | 桥环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN113666930B (zh) * | 2020-05-13 | 2022-10-25 | 上海纽思克生物科技有限公司 | 桥环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN113861220B (zh) * | 2020-06-30 | 2023-06-16 | 上海纽思克生物科技有限公司 | 三环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN113912622B (zh) * | 2020-07-10 | 2023-12-01 | 上海纽思克生物科技有限公司 | 三环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN114057740B (zh) * | 2021-12-15 | 2024-04-02 | 上海赛默罗生物科技有限公司 | 螺环嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| JP2025527291A (ja) * | 2022-08-04 | 2025-08-20 | ４ビー テクノロジーズ （ベイジン） カンパニー リミテッド | Ｌｐ－ＰＬＡ２阻害剤としてのジヒドロイミダゾピリミジノン化合物およびその使用 |
| CN121311231A (zh) * | 2023-04-18 | 2026-01-09 | 赛神医药有限公司 | Lp-PLA2抑制剂和第二药剂的联合治疗 |
| WO2025015951A1 (zh) * | 2023-07-17 | 2025-01-23 | 上海枢境生物科技有限公司 | 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用 |
| WO2025217646A1 (en) * | 2024-04-12 | 2025-10-16 | Scineuro Therapeutics Inc. | Method of treating neurodegenerative and ocular neovascular diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0127143D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| WO2004014923A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| GB0320522D0 (en) | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
| WO2009147476A1 (en) | 2008-06-02 | 2009-12-10 | Matrix Laboratories Ltd. | Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation |
| JP2013537203A (ja) * | 2010-09-20 | 2013-09-30 | グラクソ グループ リミテッド | 三環式化合物、製造方法、およびそれらの使用 |
| ES2847883T3 (es) * | 2010-12-17 | 2021-08-04 | Glaxo Group Ltd | Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares |
| CN103842362B (zh) * | 2011-05-09 | 2017-05-24 | 爱普制药有限责任公司 | 用于治疗阿尔茨海默氏病的组合物和方法 |
| CN103827118B (zh) * | 2011-07-27 | 2016-03-09 | 葛兰素集团有限公司 | 双环嘧啶酮化合物 |
| AR087309A1 (es) * | 2011-07-27 | 2014-03-12 | Glaxo Group Ltd | Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis |
| CA2842965A1 (en) * | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors |
| CN104024249A (zh) | 2011-10-17 | 2014-09-03 | 埃南塔制药公司 | 丙型肝炎病毒抑制剂 |
| JP6065786B2 (ja) | 2012-09-14 | 2017-01-25 | 信越化学工業株式会社 | 化学増幅レジスト材料及びパターン形成方法 |
| MX2015009633A (es) * | 2013-01-25 | 2015-11-30 | Glaxosmithkline Ip Dev Ltd | Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona. |
| EP2948456A4 (en) | 2013-01-25 | 2016-09-14 | Glaxosmithkline Ip Dev Ltd | BICYCLIC PYRIMIDONE COMPOUNDS AS LP-PLA2 INHIBITORS |
| CN103927116A (zh) * | 2014-03-18 | 2014-07-16 | 兴唐通信科技有限公司 | 基于触屏设备的手势输入汉字的键盘和方法 |
| AR101261A1 (es) * | 2014-07-22 | 2016-12-07 | Glaxosmithkline Ip Dev Ltd | Compuesto de tetrahidropirrolo[1,2:3,4]imidazo[1,2-c]pirimidin-1(6h)-ona y composición farmacéutica que lo comprende |
-
2015
- 2015-07-21 AR ARP150102300A patent/AR101261A1/es unknown
- 2015-07-21 BR BR112016030939-1A patent/BR112016030939B1/pt active IP Right Grant
- 2015-07-21 KR KR1020177001425A patent/KR20170029516A/ko not_active Withdrawn
- 2015-07-21 WO PCT/CN2015/084607 patent/WO2016011931A1/en not_active Ceased
- 2015-07-21 ES ES15825267T patent/ES2747636T3/es active Active
- 2015-07-21 JP JP2017503504A patent/JP6625603B2/ja active Active
- 2015-07-21 AU AU2015292048A patent/AU2015292048B2/en not_active Ceased
- 2015-07-21 TW TW104123494A patent/TW201617348A/zh unknown
- 2015-07-21 EP EP15824385.7A patent/EP3172208B1/en active Active
- 2015-07-21 RU RU2017105353A patent/RU2690190C2/ru not_active IP Right Cessation
- 2015-07-21 CA CA2955910A patent/CA2955910C/en active Active
- 2015-07-21 ES ES15824385T patent/ES2744339T3/es active Active
- 2015-07-21 JP JP2017503553A patent/JP6625604B2/ja active Active
- 2015-07-21 KR KR1020177001423A patent/KR20170034889A/ko not_active Withdrawn
- 2015-07-21 EP EP15825267.6A patent/EP3172211B1/en active Active
- 2015-07-21 RU RU2017105476A patent/RU2017105476A/ru not_active Application Discontinuation
- 2015-07-21 CN CN201580039345.0A patent/CN106536521B/zh active Active
- 2015-07-21 US US15/327,706 patent/US10125141B2/en active Active
- 2015-07-21 UY UY0001036224A patent/UY36224A/es unknown
- 2015-07-21 WO PCT/CN2015/084606 patent/WO2016011930A1/en not_active Ceased
- 2015-07-21 AU AU2015292049A patent/AU2015292049B2/en not_active Ceased
- 2015-07-21 CN CN201580040421.XA patent/CN106536525B/zh active Active
- 2015-07-21 CA CA2970537A patent/CA2970537C/en active Active
- 2015-07-21 US US15/327,685 patent/US9783546B2/en active Active
-
2018
- 2018-09-27 US US16/143,788 patent/US10428078B2/en active Active
-
2019
- 2019-07-29 US US16/524,238 patent/US11999746B2/en active Active
-
2024
- 2024-04-25 US US18/646,178 patent/US20240300965A1/en active Pending